Sarah El-Nakeep

Dr. Sarah El-Nakeep


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Arab Journal of Gastroenterology
Verified
Journal Article
Closed access
AHAbd Elkhalek Hamed
Abd Elkhalek Hamed
MEMedhat Elsahar
Medhat Elsahar
NENadia M. Elwan
Nadia M. Elwan
SESarah El-Nakeep
Sarah El-Nakeep
MNMervat Naguib
Mervat Naguib
SMShorouk Moussa
Shorouk Moussa

6 June 2016 in Expert Review of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
AEAhmed H. F. El-Tawdi
Ahmed H. F. El-Tawdi
marwa matbolimarwa matboli
marwa matboli
SESarah El-Nakeep
Sarah El-Nakeep
AAAhmed E. M. Azazy
Ahmed E. M. Azazy
OAOmar Abdel-Rahman
Omar Abdel-Rahman
Background: Long noncoding RNAs(lncRNAs) have emerged as key elements in modulating gene expression in different biological contexts. Patients and methods: We used quantitative real-time PCR (Qpcr) to evaluate the expression of lncRNA-UCA1 and C-JUN in serum of 70 patients with hepatocellular carcinoma (HCC), 32 patients chronic hepatitis C (CHC) and 38 healthy subjects and their correlation with different clinicopathological factors. Results: The expression of lncRNA-UCA1 and C-JUN was positive in 91.4%HCC patients with strong discriminating power between HCC and healthy subjects and CHC patients as well. The median follow up period was 29 months. The survival analysis showed that both lncRNA-UCA1 and C-JUN were independent prognostic factors. Of note, we identified C-JUN expression changes consistent with the lncRNA-UCA1 target regulation. Conclusion: This information sheds light on the possible role of lncRNA-UCA1 and C-JUN mRNA as promising diagnostic and prognostic markers as well as potential therapeutic targets in HCC.

13 May 2022 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
SESarah El-Nakeep
Sarah El-Nakeep
ASAhmed Shawky
Ahmed Shawky
SASara F Abbas
Sara F Abbas
OLOsama Abdel Latif
Osama Abdel Latif

14 February 2018 in Biomarkers in Medicine
Verified
Journal Article
Closed access
MAMahmoud A Ali
Mahmoud A Ali
marwa matbolimarwa matboli
marwa matboli
Nashwa El-KhazragyNashwa El-Khazragy
Nashwa El-Khazragy
OSOsama Saber
Osama Saber
SESarah El-Nakeep
Sarah El-Nakeep
RMRanda Mostafa
Randa Mostafa
Aim: We aimed to examine the statistical association between serum expression of miRNA 661 (miR-661) and ATG-4B mRNA and hepatocellular carcinoma (HCC) based on in silico data analysis followed by clinical validation. Patients & methods: Quantitative reverse-transcriptase real-time PCR was used to examine the expression of miR-661 and ATG-4B mRNA in the sera of HCC patients versus control. Results: The expression of miR-661 and ATG-4B mRNA was positive in 97.14 and 77.14%, respectively, in HCC patients. The survival analysis showed that ATG-4B mRNA was an independent prognostic factor. Conclusion: Our data are the first report of its kind regarding the considerable clinical significance of miR-661 and ATG-4B mRNA in HCC patients.

7 February 2017 in Expert Review of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
SESarah El-Nakeep
Sarah El-Nakeep
NRNoha Rashad
Noha Rashad
HOHani Oweira
Hani Oweira
JSJan Schmidt
Jan Schmidt
DHDaniel Helbling
Daniel Helbling
OAOmar Abdel-Rahman
Omar Abdel-Rahman
Introduction: We aimed to assess the efficacy and safety of delivering intraperitoneal chemotherapy and cytoreductive surgery for peritoneal metastases coupled with curative treatment of colorectal liver metastases. Areas covered: A comprehensive literature search using PubMed was conducted to screen for eligible records. Studies evaluating colorectal surgery and intraperitoneal chemotherapy combined with curative treatment of liver metastases were included. We excluded duplicate publications. Sixty-seven full-text papers were assessed and six papers were finally included. The overall survival in the included studies ranged from 6–49 months. Five-year survival ranged from 18%-28%, three-year survival ranged from 22%-42% and two-year survival ranged from 34%-78%. Survival was lower in patients with liver metastases and peritoneal carcinomatosis (PC) than those with PC alone in the majority of studies. Expert commentary: This review poses questions rather than presenting answers. The heterogeneity of survival data suggests the possible benefit of this aggressive treatment approach in selected patients. Standardization of the technique used for intraperitoneal chemotherapy instillation, agent used as well as the systemic chemotherapy and targeted therapy type and duration through prospective controlled trials is required to provide an evidence of a higher strength to support or prohibit this treatment strategy.

22 January 2022 in World Journal of Gastrointestinal Pathophysiology
Verified
Journal Article
Open access
SESarah El-Nakeep
Sarah El-Nakeep
Hepatocellular carcinoma (HCC) is the second cause of cancer-related mortality. The diagnosis of HCC depends mainly on -fetoprotein, which is limited in its diagnostic and screening capabilities. There is an urgent need for a biomarker that detects early HCC to give the patients a chance for curative treatment. New targets of therapy could enhance survival and create future alternative curative methods. In silico analysis provides both; discovery of biomarkers, and under standing of the molecular pathways, to pave the way for treatment development. This review discusses the role of in silico analysis in the discovery of biomarkers, molecular pathways, and the role the author has contributed to this area of research. It also discusses future aspirations and current limitations. A literature review was conducted on the topic using various databases (PubMed, Science Direct, and Wiley Online Library), searching in various reviews, and editorials on the topic, with overviewing the author’s own published and unpublished work. This review discussed the steps of the validation process from in silico analysis to in vivo validation, to incorporation into clinical practice guidelines. In addition, reviewing the recent lines of research of bioinformatic studies related to HCC. In conclusion, the genetic, molecular and epigenetic markers discoveries are hot areas for HCC research. Bioinformatics will enhance our ability to accomplish this understanding in the near future. We face certain limitations that we need to overcome.